USA VC Funds

Ascent Venture Partners is a Boston-based venture capital firm founded in 1985, making it one of the longest-established early-stage technology investors in the eastern United States. With $500 million in assets under management across five venture funds, Ascent has backed over 110 early-stage B2B technology companies since inception, generating more than $10 billion in enterprise value. The investment team is led by General Partners Luke Burns, Matt Fates, and Geoff Oblak, supported by CFO Tom Scanlon and a team of eight. The firm invests primarily in East Coast startups at pre-seed and seed stages, writing initial checks of $2 million to $5 million in enterprise SaaS, software, B2B platforms, cybersecurity, and data analytics. With 160 total investments and 78 exits, Ascent's track record spans nearly four decades of enterprise technology cycles — from client-server through cloud-native. The most recent investment was in Symx.Ai, a business and productivity software company, in June 2023. Ascent's four decades of institutional enterprise investing have produced something few early-stage funds can claim: a genuine alumni network of more than 100 portfolio companies whose founders and executives serve as ongoing references, co-investors, and advisors. The firm's approach combines early-stage conviction with board-level engagement from inception through exit, building partnerships that operate over the full arc of company development rather than just the initial funding event.

Asimov Ventures is an early-stage venture capital firm with offices in New York City and Palo Alto. The firm focuses on investing in cutting-edge technologies such as 3D printing, robotics, and advanced computing. Asimov Ventures seeks to partner with visionary entrepreneurs dedicated to transforming their industries through innovative solutions. Notable investments by Asimov Ventures include Particle3D, which specializes in 3D-printed bone implants, and Kadena, a blockchain technology company. The firm also invests in various other sectors, including healthcare, e-commerce, and augmented reality, reflecting their broad interest in transformative technologies​. Asimov Ventures typically participates in funding rounds with other notable investors, providing capital and strategic support to help startups scale and succeed. Their investment strategy emphasizes early-stage companies with strong intellectual property and commercial potential​.

Aspect Ventures, founded in 2014 by Jennifer Fonstad and Theresia Gouw, is a leading venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments, primarily in Series A rounds, across various sectors including cybersecurity, fintech, digital health, and enterprise software. Notable investments include Gusto, a cloud-based HR management platform; Chime, a digital bank; and Exabeam, a cybersecurity company. Aspect Ventures has had several successful exits such as Forescout Technologies, Imperva, and Trulia.

Asset Management Ventures (AMV) is a Palo Alto-based venture capital firm founded in 1965 by Pitch Johnson, one of Amgen's co-founders — making it one of the longest continuously operating VC firms in Silicon Valley. The firm specializes in early-stage investments in digital health, technology, and life sciences, and raised its fifth and largest fund at $150 million in 2020. Partners Skip Fleshman and Lou Lange lead the current investment team, which combines scientific, engineering, and medical expertise with decades of investing experience. With 152 investments and 29 exits, AMV's historical portfolio includes Amgen itself, Tandem Computer, and Applied BioSystems — foundational companies in their respective industries. The current portfolio includes Reify Health, Evidation Health, Lark, Twist Bioscience (TWST), Freenome, Welldoc, ViewPoint Therapeutics, Aavia, and 3T Biosciences, reflecting AMV's sustained focus on health technology and life sciences innovation. The firm leads rounds and deploys $1 million to $15 million across seed through Series B stages. AMV's six-decade track record is its most distinctive asset: the firm has seen multiple complete technology and healthcare cycles, giving the investment team a depth of pattern recognition and investor network that newer funds cannot replicate. The founding connection to Amgen also provides an ongoing cultural orientation toward building enduring life sciences companies rather than optimizing for short-cycle exits — an orientation that informs how AMV partners with founders over the long arc of company development.

Astarte Ventures is a Yardley, Pennsylvania-based venture capital fund founded in 2013 by Tracy Warren, recognized as the first venture fund dedicated exclusively to the health and wellbeing of women and children. As a first-mover in FemTech investing — well before the category had a name — Warren built a concentrated portfolio anchored in early intervention and prevention, spanning healthtech, life sciences, and technology sectors that improve outcomes for mothers, women, and children. Warren also serves as a mentor at Harvard's Wyss Institute. The fund has made eight investments at seed and Series A stages with checks of $500K to $3 million. Two outcomes define the portfolio's credibility: Maven Clinic, which became the largest virtual clinic for women's and family health and achieved unicorn status in 2021, and Alydia Health, acquired by Organon for $215 million in March 2021. These exits anchor the fund's FemTech track record against a backdrop of concentrated, conviction-led investing. Astarte Ventures' small portfolio size is intentional — Warren's model prioritizes deep engagement with each company over broad deployment. Each portfolio company benefits from Tracy Warren's domain expertise in female health outcomes and impact investing, as well as her network across academic medicine, women's health advocacy, and the broader healthcare industry. For founders in FemTech, backing from Astarte carries the credibility of the category's earliest and most dedicated institutional champion.

Astellas Venture Management (AVM) is the wholly-owned corporate venture capital arm of Astellas Pharma, one of the world's leading pharmaceutical companies. Founded in 2005 and headquartered in South San Francisco, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies for over twenty years. The investment thesis is explicitly strategic: AVM targets science that enhances the Astellas R&D pipeline or catalyzes new directions in discovery research, with the team's Pharma View serving as both a selection lens and a support framework. AVM has invested in 61 companies across 104 total investment rounds, deploying $3 million to $20 million per company at seed through Series B stages. Series A is the most active stage, with 19 investments averaging $33.8 million in round size. Notable current portfolio companies include Solu Therapeutics, Syntax Bio, PhoreMost, and Somite. The most recent investment was in Solu Therapeutics in April 2025, and the most recent exit was Orna Therapeutics in February 2026. A team of eight, including three partners and one principal, spans the US and Japan. AVM's principal value to portfolio companies is its deep pharmaceutical industry expertise and the pathway it opens to Astellas Pharma: strategic licensing dialogues, research collaborations, and potential acquisitions that purely financial investors cannot facilitate. For early-stage biotech founders, AVM's Pharma View means receiving guidance from investors who understand drug development not as outsiders but as participants in the global pharmaceutical system.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Asymmetric Financial is a venture capital firm that focuses on investing in early-stage companies within the fintech, software, and digital health sectors. Founded by Joe McCann in 2022, the firm operates with a unique approach to venture capital, combining deep expertise in technology and finance to support companies that are poised to disrupt traditional industries. Asymmetric Financial aims to identify and back innovative startups that leverage advanced technologies such as artificial intelligence, blockchain, and big data analytics to create new market opportunities. The firm’s investment strategy is centered on providing not only capital but also strategic guidance and operational support. Asymmetric Financial works closely with its portfolio companies to help them scale efficiently, offering assistance in areas such as financial planning, go-to-market strategies, and key performance indicator (KPI) development. This hands-on approach ensures that the startups in their portfolio are well-equipped to navigate the challenges of rapid growth and market competition. Asymmetric Financial is particularly interested in companies that have the potential to generate significant returns while also creating meaningful impact through their innovations. By focusing on sectors that are at the intersection of technology and finance, the firm aims to contribute to the modernization and transformation of the financial services industry.

Asymmetric Capital Partners (ACP) is a venture capital firm focused on backing B2B technology companies from Seed to Series C stages. Founded in 2020 by Rob Biederman, former co-CEO of Catalant Technologies, ACP manages an oversubscribed debut fund of $105 million. The firm targets disruptive businesses in areas like healthcare IT, fintech, marketplaces, and next-gen software, especially those transforming legacy industries and capitalizing on digital innovation. ACP is known for its hands-on approach, leveraging a team of founders and former operators who work closely with startups on strategic growth areas such as hiring, go-to-market strategies, and financial planning. They typically invest between $2M to $10M, with the flexibility to co-invest in larger deals alongside top firms like Andreessen Horowitz and Sequoia Capital. Some notable investments include Firstbase, a remote work platform backed by Andreessen Horowitz, and Clearco, a fintech company. The firm prides itself on being deeply involved with its portfolio companies, providing both operational support and access to a vast network of advisors and industry experts.

Asymmetry Ventures, based in San Francisco, is a prominent early-stage venture capital firm founded by Rob Ness. The firm focuses on investing in transformative startups that have the potential to create significant impact. They have a diverse portfolio of over 280 investments, including notable companies like BillionToOne, Foresight Mental Health, Mast Reforestation (formerly DroneSeed), and Orbit Fab. Asymmetry Ventures is known for their commitment to supporting defensible businesses, particularly in sectors such as artificial intelligence, biotechnology, and aerospace. They typically make initial investments in the range of $2 million and have been involved in notable funding rounds such as Orbit Fab's $10 million raise, which also saw participation from major aerospace players like Northrop Grumman and Lockheed Martin. The firm prides itself on identifying and backing visionary founders and innovative business models, with a strong emphasis on early-stage investments that leverage technology to create natural barriers to entry and generate recurring revenue streams. They also prioritize investments that address significant market needs with scalable solutions. For startups looking to partner with Asymmetry Ventures, demonstrating a strong leadership team and a clear path to market dominance are crucial. The firm's deep network and extensive industry experience provide valuable support and guidance to their portfolio companies, enhancing their potential for growth and success.

AT Inc, now known as Amazon Catalytic Capital, is Amazon’s venture capital initiative with an initial commitment of $150 million aimed at supporting underrepresented founders. The fund invests in venture capital funds, accelerators, incubators, and venture studios that prioritize startups led by Black, Latino, Indigenous, women, and LGBTQIA+ entrepreneurs. This initiative not only provides financial backing but also offers mentorship from Amazon executives and access to resources that can aid in business and technical strategy. Key investments include Collide Capital, Elevate Future Fund, Share Ventures, and Techstars Rising Stars Fund. These funds focus on diverse founders working in areas such as clean energy, fintech, health tech, and consumer goods. Amazon’s goal is to foster inclusion and innovation, ultimately driving economic growth and creating generational wealth for historically underserved communities.

At One Ventures is a venture capital firm founded in 2020 by Tom Chi, a founding member of Google X. The firm is dedicated to investing in early-stage startups that are developing disruptive deep tech solutions aimed at making humanity a net positive to nature. With a strong focus on climate tech, At One Ventures has established itself as a significant player in the industry. The firm recently closed its second fund at $375 million, indicating strong investor confidence and a robust commitment to supporting climate-positive innovations. This fund follows their initial $150 million fund and aims to support startups that can dramatically reduce environmental footprints while upending established industrial economics. At One Ventures' investment portfolio includes companies across various sectors such as renewable energy, sustainable agriculture, and advanced materials. Notable investments include Noon Energy, which focuses on long-duration energy storage, and MightyFly, which is developing hybrid electric drone delivery systems. The firm's approach is hands-on, providing strategic guidance in talent acquisition, operations, marketing, IP strategy, and manufacturing. The team at At One Ventures consists of experienced professionals with backgrounds in physical sciences, engineering, manufacturing, and finance, ensuring a deep understanding of the technologies and markets they invest in. They operate globally, with a presence in San Francisco and London, and continue to seek partnerships with entrepreneurs, scientists, and investors who share their vision for a sustainable future.

at.inc/, originally founded in 2015 as Tank Hill Ventures, is a boutique seed-stage venture capital firm that partners with founders 'at incorporation,' backing startups at the earliest possible stage, sometimes as early as the idea phase, then providing continuity, capital and support throughout the venture journey. Operating across Silicon Valley and Israel, the firm leads seed rounds with conviction and concentrates on technology startups with disruptive business models, with top sectors in enterprise applications and enterprise infrastructure. Geographically its portfolio skews to the United States, around 60%, Israel, around 20%, and the United Kingdom, around 20%. The firm is led by Managing Partner Nadav Eylath, who has led seed investments in Netlify, Wescover, Disclosures.io, HoneyBook, Future Family, Opendoor (IPO) and Peer5 (acquired by Microsoft); General Partner Roni Bonjack brings operating experience having built and led global startup programs for Google and Facebook. After its first fund reportedly returned over 10x, the firm raised an oversubscribed $35M Fund II under the at.inc/ brand. By its own account it has made 58 investments with 12 exits, one IPO and four unicorns, including Netlify, HoneyBook and Placer.ai. Notable recent deals include leading Bagel AI's $5.5M seed in April 2025, a $3.0M seed in Podqi in March 2025, HelloCity's $585K pre-seed in 2024 and Stack's seed round in 2024. Early signature wins include leading Netlify's $2.1M seed in 2016 alongside the founders of GitHub, Heroku and Rackspace. at.inc/ specializes in being the very first institutional partner to technical founders.

ATA Ventures is a Redwood City, California-based venture capital firm founded in 2003 by Hatch Graham and Pete Thomas, with over $450 million of capital under management. The firm focuses on digital delivery platforms that empower business and consumer applications — specifically, investments where long-standing, outdated procedures can be replaced with technology-rich solutions. The founding partners bring decades of proven operating experience to portfolio companies, complementing capital with strategic guidance from people who have built technology businesses themselves. ATA leads rounds and deploys $1 million to $10 million at seed and Series A stages, with a portfolio concentrated in enterprise SaaS, software, B2B platforms, and data analytics. With 119 investments and 24 exits, the firm has a track record spanning over two decades across multiple enterprise technology cycles. Top portfolio areas include enterprise applications (18 investments) and enterprise infrastructure (9 investments), with the firm located at 203 Redwood Shores Parkway in the heart of Silicon Valley. Graham and Thomas built ATA around a clear operating philosophy: the best venture returns come from backing companies solving genuine enterprise inefficiencies, and the best support an investor can offer is operational experience — not just pattern recognition from watching other companies. The firm's proximity to major technology companies in the Bay Area, combined with more than twenty years of ecosystem relationships, provides portfolio companies with access to potential partners, customers, and talent throughout their growth trajectories.

Ataria Ventures is a Peru-based venture capital firm founded in 2017 by Managing Partners Alejandro Ponce and JP Ortiz, headquartered in San Isidro, Lima. The firm serves as a structured gateway for Latin American investors and corporations to engage with the world's leading technology ecosystems, combining direct venture investment with corporate venture building. It has completed more than 50 deals, with a direct portfolio of 15-plus companies and a broader network of over 40 companies worldwide. Ataria invests primarily at seed and Series A stages, with checks ranging from $100,000 to $2 million, across artificial intelligence, big data, agritech, foodtech, consumer, and health sectors in Latin America and the United States. Notable portfolio companies include Beam and GoTrendier. The founding partners bring backgrounds in venture investing, private equity, and digital transformation — a combination that positions the firm to bridge Latin American capital with global technology opportunities. The firm's core differentiation is its Corporate Venture Capital and Venture Building model, which offers Latin American corporates a structured pathway into startup innovation without building in-house venture teams from scratch. By combining investment with co-creation of digital businesses, Ataria helps established corporations participate meaningfully in the technology ecosystem while providing portfolio founders with access to corporate distribution channels and regional scale.

Atento Capital is a Tulsa-based venture capital firm founded with the mission of supporting early-stage tech startups, particularly those in underinvested communities. The firm was launched with backing from the George Kaiser Family Foundation, focusing on generating both market returns and social impact by funding innovative companies in the Heartland region of the U.S. Atento primarily invests in seed and early-stage companies, with check sizes ranging from $250,000 to $3 million. They are committed to fostering diversity in entrepreneurship, directing nearly half of their capital to underrepresented founders, including women and founders of color. Notable portfolio companies include RobbieAI, a platform using computer vision to prevent patient injuries, and PatchRx, a health tech solution aimed at improving medication adherence​. Beyond funding, Atento provides hands-on support to startups by offering mentorship, business development guidance, and access to local talent via partnerships with organizations like inTulsa. Their approach is deeply rooted in building long-term success for founders who have traditionally been overlooked by the broader venture capital ecosystem.

Atlanta Ventures is an Atlanta, Georgia-based venture capital firm and startup studio founded in 2012 by David Cummings, a serial entrepreneur who built and sold 10 companies, including Pardot (acquired by ExactTarget and subsequently Salesforce). The firm focuses exclusively on fast-growing SaaS and subscription businesses in the Southeast, targeting companies with under $5 million in ARR where founder-led capital and operational support can have the greatest impact. The firm leads or fills entire rounds with investments of $250,000 to $5 million across seed through Series B stages, having backed over 25 companies. Cummings's portfolio includes some of Atlanta's most consequential technology outcomes: Craig Hyde at Rigor, Kyle Porter at SalesLoft, Eric Spett at Terminus, and Tope Awotona at Calendly — which became a $3 billion-plus unicorn. Atlanta Ventures also runs a Studio program that systematically co-founds and scales subscription businesses by pairing proven methodology with experienced operators. The firm's differentiation is its founder-operator DNA. Cummings built the Atlanta Tech Village — one of the Southeast's largest tech hubs — and integrates community, content, and capital into a comprehensive ecosystem for regional entrepreneurs. That combination of hands-on operational experience, SaaS expertise, and deep local networks makes Atlanta Ventures the anchor early-stage institution for the Southeast tech corridor.

Atlantic Vantage Point (AVP), based in Paris, is an independent global investment platform with more than $2.7 billion in assets under management. Originally founded in 2016 as the corporate venture capital arm of AXA — one of the world's largest insurance groups — the firm completed a management buyout from AXA in 2024 to become a fully independent entity, with AXA remaining as an anchor limited partner. AVP leads rounds across Europe and North America, deploying from its flagship €1.5 billion AVP Growth I fund. The firm has made 94 investments across enterprise software, fintech, insurtech, digital health, and cybersecurity, backing businesses from early growth through to late stage. With typical checks ranging from $10 million to $100 million, AVP operates as a transatlantic platform combining deep local expertise in both European and North American markets. Its heritage in insurance and financial services provides portfolio companies with a distinctive strategic lens and access to industry relationships built over years within the AXA ecosystem. AVP's investment approach emphasizes strategic guidance alongside capital, leveraging its position at the intersection of European and US technology markets to help portfolio companies scale across both geographies. The firm's scale, sector expertise, and ability to support companies across multiple funding rounds distinguish it from single-geography growth investors. Its 2024 independence marks a new phase — one defined by broader LP relationships while retaining the institutional depth of its AXA origins.

Atlas Venture is a leading biotech venture capital firm focused on creating and building innovative life science companies. With over 30 years of experience, they have incubated over 70 startups and taken 40 companies public, including Intellia Therapeutics, Kymera Therapeutics, and Generation Bio. Atlas specializes in drug discovery and development, emphasizing areas like gene editing, oncology, and immunotherapy. Headquartered in Cambridge, Massachusetts, Atlas primarily targets U.S.-based startups but maintains a global vision, partnering with top scientific minds. They invest early, often leading seed and Series A rounds, with typical check sizes ranging from $5M to $20M. Atlas's approach is hands-on, actively incubating new ventures and co-founding companies with a strong operational focus. Key figures include Jean-François Formela, who has been instrumental in several high-profile exits and IPOs, and focuses on cutting-edge drug discovery technologies. Founders approaching Atlas should focus on breakthrough science with clear therapeutic applications, as the firm seeks to translate groundbreaking research into life-changing medicines.

Atlas Venture is a leading venture capital firm specializing in early-stage investments in biotechnology and life sciences. Founded in 1980 and based in Cambridge, Massachusetts, Atlas Venture has built a robust portfolio by focusing on groundbreaking biotech innovations. The firm has raised multiple funds, including their most recent Fund XIII at $450 million, which emphasizes their commitment to fueling biotech startups from seed stage through to successful exits​. Notable investments in their portfolio include companies like Intellia Therapeutics, Kymera Therapeutics, and Ikena Oncology. These investments highlight Atlas Venture's dedication to developing therapies that address significant unmet medical needs, particularly in oncology and genetic disorders. Intellia Therapeutics, for instance, is renowned for its gene-editing technologies, while Kymera Therapeutics focuses on protein degradation to treat diseases. Atlas Venture has achieved numerous successful exits, such as the acquisitions of IFM Therapeutics by Bristol-Myers Squibb and Novartis, and the IPO of Generation Bio. These exits underscore the firm’s strategic capability in identifying and nurturing high-potential biotech startups to maturity. The firm is led by a team of experienced partners, including Jean-Francois Formela, Jason Rhodes, and David Grayzel, who bring a wealth of expertise in venture capital and life sciences. This team collaborates closely with entrepreneurs to provide not just capital but also strategic guidance and operational support, leveraging their extensive network within the biotech industry. For startups aiming to partner with Atlas Venture, it is crucial to present innovative solutions with strong scientific foundations and clear pathways to address significant medical challenges. The firm values startups that demonstrate potential for substantial clinical impact and scalability within the healthcare sector.

Atomico, founded in 2006 by Skype co-founder Niklas Zennström, is a leading venture capital firm based in London, with additional offices in Paris, Berlin, and Stockholm. The firm focuses on Series A and beyond investments in disruptive technology companies globally. Atomico's notable investments include Klarna, Truecaller, Lime, Hinge Health, and Rovio, which highlight their strong presence in fintech, healthcare, consumer tech, and gaming sectors. Atomico's investment strategy centers around partnering with mission-driven European founders, providing them with not just capital but also extensive operational support through their Growth Acceleration Team. This team assists with scaling operations, strategic planning, and navigating complex market dynamics. Their typical investment range is from $10 million to $50 million, and they often lead rounds, ensuring significant influence in their portfolio companies' trajectories. The firm is known for its diverse team and deep industry expertise. Key figures include Niklas Zennström, CEO and Partner; Chris Barnes, COO; and Thomas Wehmeier, Partner and Head of Insights, all based in London. This diverse leadership team brings a wealth of experience from various sectors, enhancing their ability to support and scale innovative startups. For startups looking to engage with Atomico, it's crucial to showcase innovative solutions with a potential for significant market impact. The firm is particularly interested in technology-driven companies that can leverage shifts in consumer behavior and technological advancements.

ATP Fund, established in 2014 and headquartered in Austin, Texas, is an early-stage venture capital firm that focuses on deep tech investments aimed at advancing human conditions through scientific innovation. The firm specializes in sectors such as artificial intelligence (AI), biotechnology, cleantech, cybersecurity, enterprise software, healthcare, and robotics. ATP Fund is known for its strategic investments in startups that are tackling some of the most challenging and impactful problems of our time. ATP Fund adopts a contrarian and hands-on approach, often partnering with scientific entrepreneurs at the earliest stages of their ventures, sometimes even at the formation stage via their Proto.n initiative. This strategy reflects their commitment to long-term partnerships and their belief in the transformative potential of cutting-edge technologies. The fund's portfolio includes a variety of high-impact companies like Diligent Robotics, which focuses on healthcare robotics, and Infleqtion, a firm that specializes in quantum technology. These investments highlight ATP Fund's dedication to supporting ventures that have the potential to make significant advancements in their respective fields. ATP Fund collaborates with a wide network of co-investors, including notable names like Texas Venture Labs and Osage University Partners. The firm has also seen successful exits, further establishing its reputation as a key player in the deep tech investment landscape.

Atria Ventures is a San Francisco-based venture capital firm founded in 2023 by General Partner Chris Leiter. The firm invests at the intersection of life sciences and artificial intelligence, partnering with founders working at the edges of biology and human health to reimagine the trillion-dollar life sciences industry from molecule to patient. Atria leads rounds at pre-seed and seed stages, with a sweet spot of $800,000 and a range of $250,000 to $2 million. Through its closed Fund I, Atria has made 15 investments across healthcare AI, biotech, and clinical development. Notable portfolio companies include Sleuth Insights in healthcare analytics, Peer AI in healthcare artificial intelligence, and Trially in clinical trials technology. The most recent investment was in Peer AI's Series A in October 2025, reflecting the firm's commitment to following its strongest portfolio companies into later rounds. Atria differentiates itself through singular focus on the convergence of computational approaches and life sciences — a sector where AI is fundamentally transforming drug discovery, diagnostics, clinical trials, and patient care delivery. Rather than investing broadly across healthcare, the firm concentrates on companies where deep learning, biological data, and clinical insight create compounding advantages. Chris Leiter's background informs a hands-on, thesis-driven approach that prioritizes founders working on problems with both scientific novelty and clear paths to clinical or commercial adoption.

ATX Seed Ventures, now operating as ATX Venture Partners, is an Austin, Texas-based early-stage venture capital firm founded in 2014 by Brad Bentz, Danielle Weiss Allen, and Chris Shonk. The firm manages more than $60 million in assets, including a $32 million second fund raised in 2019, and focuses on leading seed and Series A investments in disruptive B2B software, APIs, applications, frontier tech, and marketplaces. It leads rounds with checks averaging $2.5 million, up to $5 million per investment. ATX has invested in 26-plus companies and established itself as one of the most active early-stage funds in the Texas technology ecosystem. Notable portfolio companies include Alert Media, SourceDay, GoCo, LIFT Aircraft, Pensa Systems, QuotaPath, Slingshot Aerospace, and monoDrive — representing the breadth of its coverage across supply chain, fintech, insurtech, and frontier tech sectors. Limited partners include successful entrepreneurs, executives, institutions, and family offices. The firm rebranded from ATX Seed Ventures to ATX Venture Partners in 2019 to reflect expanded scope beyond strictly seed-stage investing. Its geographic concentration in Austin — one of the fastest-growing technology hubs in the United States — gives the team deep local relationships and access to deal flow that coastal funds often miss. The founding partners bring complementary operational and investing backgrounds, enabling hands-on support for portfolio companies navigating product development, go-to-market, and early scaling challenges.

AU21 Capital is a venture capital firm focused on investing in blockchain technology. Founded in 2017, AU21 Capital combines decades of executive and operational experience from industry leaders like Huobi and Galaxy Digital. The firm invests primarily in early-stage and seed investments, supporting companies that are pushing the boundaries of blockchain technology. AU21 Capital’s portfolio includes notable projects such as Axie Infinity, Injective, Marlin, Cere, Covalent, Casper Labs, Serum, Fantom, Harmony, Iotex, Coin98, Polkadot, and Star Atlas. The firm is known for its deep involvement in the development and growth of these companies, often collaborating with top exchanges and launchpads to bring innovative products to market. The leadership team at AU21 Capital leverages its extensive network and expertise to provide strategic guidance, business development, and market positioning for its portfolio companies. This hands-on approach ensures that the startups they back are well-equipped to navigate the challenges of the blockchain industry and achieve significant growth.

Audacia is a Paris-based private equity and venture capital firm, founded in 2006 by Charles Beigbeder. The firm focuses on a range of investment strategies, including venture capital, growth capital, and buyouts, primarily targeting high-tech, real estate, and consumer sectors. With a strong emphasis on innovation and technological advancement, Audacia has built a diverse portfolio of over 229 investments, including companies like Gamestream and Multiverse Computing. Audacia is particularly active in France, which accounts for the majority of its investments, though they also have a presence in other regions like the United Kingdom. The firm’s approach involves leading early-stage and Series A funding rounds, supporting startups through to later stages of growth. Audacia’s investment philosophy centers on backing visionary entrepreneurs and innovative companies that have the potential to disrupt their respective industries. The firm is led by a seasoned team of 20 professionals, including key figures such as Charles Beigbeder, Cedric James, and Vincent Brillault, who bring extensive experience in both the investment and operational aspects of the business. With its strategic focus and deep expertise, Audacia continues to play a significant role in shaping the European venture capital landscape​.

Audacious Ventures is a venture capital firm dedicated to supporting the world's most ambitious founders from the earliest stages of their entrepreneurial journeys. Founded in 2020, the firm has quickly made a name for itself with its unique approach that blends traditional seed-stage investing with a strong emphasis on talent acquisition for its portfolio companies. In April 2024, Audacious announced its $150 million second fund, Audacious 2.0, which continues its mission to invest in sectors such as AI, fintech, healthcare, construction tech, and climate tech. What sets Audacious apart is its deep focus on helping founders build A+ teams, particularly in critical areas like engineering, sales, and marketing. Half of Audacious' team comprises experienced recruiters who actively run searches for portfolio companies, ensuring they attract top-tier talent as they scale. This hands-on support reflects the firm’s belief that startup success hinges on exceptional teams and large market opportunities. Audacious Ventures has invested in several high-growth companies, including Vartana, Multiverse, Suppli, and Ignition. These investments underscore the firm’s commitment to backing startups that have the potential to become industry leaders. Unlike many venture firms, Audacious does not take board seats, preferring instead to focus on providing value through strategic hiring support and then stepping back to let founders lead their companies to success​.

Ault Krug Ventures (AK Ventures) is a San Francisco-based pre-seed and seed venture capital firm founded in late 2015 by Joey Krug and J. Henry Ault. The firm invests in early-stage companies — typically before product-market fit — focused on advanced software and hardware applications. Through its AngelList syndicate, AK Ventures has deployed over $3 million with realized returns exceeding 7x, establishing a track record that belies its small fund size. The investment sweet spot is $300,000, with a range from $100,000 to $1 million, directed primarily at software, web3, AI, and fintech companies in the United States. Joey Krug also serves as co-Chief Investment Officer at Pantera Capital, one of the largest digital asset investment firms, bringing deep expertise in cryptocurrency and blockchain to the partnership. Henry Ault co-founded Beam, a payments-focused cryptocurrency, alongside Krug and other collaborators in 2017, giving the firm firsthand operator experience in fintech infrastructure. AK Ventures operates with a hands-on investment philosophy, helping founders clarify vision, direction, and communication while providing practical support in fundraising, selling, hiring, and navigating technical challenges. The dual expertise of its founders — spanning traditional software startups and digital assets — gives the firm a distinctive lens for evaluating companies at the intersection of these converging sectors. The firm's operator-first approach and willingness to engage at the earliest pre-traction stages define its character as an investor.

Aurum Ventures M.K.I is a Ramat Gan, Israel-based growth capital firm founded in 2005 as the venture capital vehicle of Morris Kahn, the prominent Israeli businessman and philanthropist who served as former chairman of Amdocs. The firm provides value-added capital to exceptional entrepreneurs in life sciences and clean technology, investing primarily at Series A, B, and later stages in companies with demonstrated clinical or commercial traction. Aurum has invested in 15 companies across biotech, clean tech, health technology, and pharma, with notable portfolio companies including LifeBond, Nephera, and BPT. The firm leads rounds with checks typically between $3 million and $20 million. Over its history, 55 co-investors have participated in Aurum's portfolio companies, including institutional names such as TELUS Ventures, RA Capital Management, and BlackRock — a reflection of the caliber of deal flow the firm sources. Aurum Ventures' core competitive advantage is the network, credibility, and industry relationships that come with the backing of Morris Kahn — one of Israel's most respected business leaders. Portfolio companies benefit from strategic guidance grounded in decades of operating and investing experience in the Israeli and global technology landscape. The firm's focus on life sciences and clean tech positions it at the intersection of two sectors where Israel has developed notable scientific and engineering depth, and where patient, relationship-driven capital creates meaningful differentiation at growth stage.

Austin Ventures is an Austin, Texas-based private equity and venture capital firm founded in 1984 — one of the earliest and most influential venture institutions in the American Southwest. For more than three decades, it was the largest and most active venture capital firm in Texas, raising approximately $3.9 billion across ten funds and deploying nearly $3 billion into companies across the Lone Star State. The firm focuses on venture capital and growth equity in business services, supply chain, financial services, new media, internet, and information technology, with particular concentration on Texas-based companies. Austin Ventures invested in more than 200 companies across its history, targeting early-stage and middle-market businesses led by talented executives and entrepreneurs building industry-leading companies. The firm leads rounds with checks ranging from $3 million to $50 million. Its long tenure at the center of the Texas tech ecosystem gave it foundational relationships with the entrepreneurs and institutions that built Austin into a nationally significant technology hub. By 2015, the firm's general partners began transitioning toward buyout investing rather than traditional venture activity, reflecting a natural evolution after three decades of early-stage work. Austin Ventures' legacy is most visible in the ecosystem it helped build: its investments, exits, and the founders it backed over four decades shaped the culture and infrastructure of Texas technology entrepreneurship. The firm remains a reference point for the history and maturation of venture capital in markets outside coastal technology centers.

Authentic Ventures is a venture capital firm based in Oakland, California, focused on seed and early-stage investments. Founded in 2016 by Lindsay Lee JD, the firm targets a diverse range of industries, including enterprise software, consumer products, digital health, and deep tech sectors. Authentic Ventures emphasizes the importance of diversity and inclusivity, actively seeking to support women and minority founders who are tackling significant problems. The firm manages a concentrated portfolio, making 4-6 new investments annually, and works closely with its portfolio companies to ensure their success. Some notable investments include Verbal, Humans Anonymous, and Credit Mountain, highlighting their commitment to innovation and impactful solutions across various sectors. Authentic Ventures' team comprises experienced professionals, including Robin Bordoli, Amel Abdelwahid, and Michael Nichols JD, who collectively bring deep expertise in finance, compliance, and operations. The firm leverages a robust network to provide startups with the resources and connections needed to thrive.

Autochrome Ventures is a Los Angeles-based inception and seed stage venture capital fund founded in 2016 by Vaughn Blake, who also leads Autochrome Capital Management. The firm invests in the technology sector with a particular emphasis on applied frontier and emerging technologies — areas where advances in science and engineering are being translated into new markets and business models. Autochrome engages at the earliest stages of company formation, often before conventional product milestones exist. The firm has built a portfolio of 21 companies across AI and deep tech, biotech, software, and clean technology, with checks ranging from $100,000 to $1 million. A notable portfolio investment is Tropic Biosciences, an agricultural biotech company, reflecting the fund's appetite for technically complex, science-driven ventures. Autochrome's last recorded investment was in April 2020, suggesting the fund has been in a harvesting or transitional phase. Autochrome differentiates itself through a willingness to engage before a company has fully taken shape — funding founders at the inception stage when capital is scarce and direction is still being established. Based in the Los Angeles technology ecosystem, the firm provides early-stage founders with capital and strategic guidance during the most formative period of company building. Its focus on frontier technology applications — spanning machine learning, biotech, and clean energy — reflects a thesis that the most significant value creation happens at the earliest intersection of emerging science and entrepreneurial ambition.

Autonomy Ventures is a New York-based early-stage venture capital fund founded in 2016 by Oliver Mitchell, Gary Lubin, and Lynn Greenberg. Lubin previously served as a founding member of Merck Capital Ventures, a $100 million-plus medical devices and healthcare IT fund, while Greenberg joined from Bloomberg — together giving the partnership depth across financial services and health technology. The firm focuses on seed and Series A investments in artificial intelligence, robotics, IoT, and smart device technologies. Autonomy has made 27 investments across the United States and Israel, including Angular Finance, Bumper, and Ingress-Health in sectors spanning fintech, mobility, and healthcare. Checks typically range from $500,000 to $3 million, deployed into companies building business products and services across AI, cybersecurity, SaaS, advanced manufacturing, infrastructure, and machine learning. The dual geography — US and Israel — reflects the partners' recognition that Israel's deep tech talent pool produces particularly strong companies in AI and security. The firm's thesis centers on the convergence of artificial intelligence, robotics, and connected devices — technologies that are increasingly embedded in industrial, commercial, and consumer contexts. Autonomy invests at the point where these technologies are moving from proof-of-concept to early commercial adoption, a stage where capital and strategic guidance can accelerate meaningful scale. The combination of financial services expertise from Lubin, media and data experience from Greenberg, and Oliver Mitchell's founding partnership creates a team with broad perspectives on how intelligent systems create enterprise value.

Autotech Ventures, based in Menlo Park, California, is an early-stage venture capital firm with a mission to solve global ground transportation challenges through technology. The firm manages over $500 million and invests in startups from seed to Series C stages that focus on connectivity, autonomy, shared-use, electrification, and digitization of enterprises. Autotech Ventures has an impressive portfolio that includes notable investments such as Lyft, Cazoo, SpotHero, Volta, and Outdoorsy. They have a history of successful exits, including Bear Flag Robotics, acquired by John Deere, and nuTonomy, acquired by Delphi. Their investment strategy often involves initial investments ranging from $1 million to $8 million, and they are known for their deep industry expertise and strong network within the transportation sector. The team, led by managing directors Quin Garcia and Daniel Hoffer, combines decades of experience in both the ground transport and venture capital industries. This allows them to identify and support startups that have the potential to disrupt traditional transportation models or introduce significant innovations in the field. Autotech Ventures prides itself on a founder-first philosophy and actively supports its portfolio companies by leveraging its extensive network of industry insiders, including fleet operators, vehicle manufacturers, and energy companies. This approach not only helps startups gain critical industry connections but also facilitates strategic partnerships and acquisitions.

AV8 Ventures is a venture capital firm with a focus on early-stage investments in technology and healthcare sectors. Founded by George Ugras, who brings extensive experience from IBM Ventures and Apax Partners, AV8 Ventures operates primarily from Palo Alto and London. The firm leverages its deep expertise in applied AI, cloud computing, and big data to support transformative startups in these fields. The firm's investment strategy centers on identifying high-potential startups and providing them with not only capital but also strategic support and industry connections. AV8 Ventures emphasizes building long-term relationships with its portfolio companies, helping them scale and succeed in competitive markets. Notable investments by AV8 Ventures include companies like GrayMatter, which develops smart robotic solutions for manufacturing, and Precision Neuroscience, focusing on groundbreaking brain technology. These investments highlight AV8's commitment to supporting innovative technologies that address significant challenges in their respective industries. The team at AV8 Ventures, led by Ugras, comprises experienced professionals with backgrounds in venture capital, entrepreneurship, and technology development. This diverse expertise enables AV8 to provide comprehensive support to its portfolio companies, guiding them through various stages of growth and development. For startups looking to partner with AV8 Ventures, it’s essential to demonstrate strong technological foundations, clear market potential, and a vision for scalability and impact in the technology or healthcare sectors​.

Avalanche VC is a forward-thinking venture capital firm focused on transformative technologies at the intersection of how people learn, earn, and own. Founded by Katelyn Donnelly, Avalanche invests in early-stage startups that have the potential to ignite massive shifts in society—what they refer to as "avalanches." Their portfolio reflects this vision, featuring investments in groundbreaking companies like Agora, Humanly, and Bluesky. They are particularly drawn to sectors like EdTech, AI, and platforms that empower individuals to gain more autonomy in work and ownership. Geographically, Avalanche VC operates globally, with a strong emphasis on North America and Europe, always on the lookout for companies that can disrupt traditional systems on a massive scale. Their investment strategy is rooted in deep research and proprietary insights. They tend to invest early, typically with checks averaging around $1 million, and often prefer to follow rather than lead rounds. They are known for backing founders with a long-term vision—those who view their startups as their life’s work. Avalanche’s team brings a wealth of experience from tech, education, and government sectors, making them highly equipped to support portfolio companies beyond capital with strategic guidance and industry expertise. Startups looking to connect should emphasize their commitment to systemic change and demonstrate a clear understanding of the trends Avalanche is betting on for the future.

Avalon BioVentures, based in La Jolla, California, is a leading venture capital firm dedicated to early-stage biomedical innovation. With a $135 million fund, ABV1, Avalon BioVentures continues the legacy of Avalon Ventures by focusing exclusively on life sciences. Notable investments include Vertex Pharmaceuticals, Onyx Pharmaceuticals, Amira Pharmaceuticals, and Neurocrine Biosciences. More recent successes include Sitari Pharmaceuticals (acquired by GSK), Calporta (acquired by Merck), and Synthorx (acquired by Sanofi). Avalon BioVentures concentrates on biotechnology and life sciences, investing primarily in companies that are developing groundbreaking therapies for unmet clinical needs. Geographically, the firm focuses on the U.S., leveraging its strong presence in San Diego’s vibrant biotech hub. The firm’s strategy involves more than just capital; it includes active partnership through their integrated life science accelerator, providing essential resources, operational support, and strategic guidance from day one. Avalon BioVentures typically leads investment rounds, with average checks ranging from early seed funding to larger Series A investments. Key team members include Jay Lichter, Ph.D., an experienced biotech executive, Sanford J. Madigan, Ph.D., who has a rich background in corporate financing and business development, and Sergio G. Duron, Ph.D., known for his extensive experience in drug discovery and preclinical development. These leaders, among others, bring a combination of scientific expertise and entrepreneurial acumen, ensuring a hands-on approach to building successful biotech companies. Startups seeking investment should approach Avalon BioVentures with a clear vision for innovation in life sciences and a readiness to engage in a collaborative, entrepreneurial partnership.

Avant Global is a relationship-driven private investment firm founded in 1999, focused on leveraging high-level connections to foster innovative and high-growth companies. The firm has a global presence with offices in the USA, Greece, and the Philippines, and invests across various sectors including technology, healthcare, real estate, and consumer products​. Notable portfolio companies include The Healing Company, which focuses on healthcare and retail, Equiam, specializing in venture capital and asset management, and Jawbone Health, an information services and wellness company. Other significant investments are in innovative firms like Iron Ox, a leader in agricultural robotics, and BlueLayer, a software company based in Berlin​. The firm's founder and CEO, Demetri Argyropoulos, is known for his extensive network and strategic vision, having co-founded and invested in over 100 companies. He leads a seasoned team, including Executive Director George Vassilaras, who brings decades of experience in diverse industries and geographies​.

Aventurine Capital Group, based in Palo Alto, California, is a venture capital firm specializing in deep tech and IP-focused investments. The firm leverages a unique asset class, known as The PIPI Fund, designed to support new science ventures through long-term management and strategic IP development. This fund addresses the unique needs of deep tech companies by providing commercialization support for inventors, scientists, and research entrepreneurs. Aventurine Partners, on the other hand, focuses on Mitigation & Adaptation investing. The firm targets opportunities that promote decarbonization and long-term energy transition, partnering with businesses that work towards reducing greenhouse gas emissions and enhancing climate resilience. Their flexible investment mandate supports companies with varying capital needs, leveraging extensive expertise in power, renewables, and transition technologies. Aventurine Partners collaborates with Carnelian Energy Capital to pursue these strategies. Key team members include Andrew Adler, a partner based in Los Angeles with a background in business development for Oaktree Capital Management, and other principals with deep expertise across the energy landscape. Aventurine's notable investments include initiatives that contribute to tangible decarbonization and capitalize on their extensive industry relationships and experience to add significant value. For startups looking to engage with Aventurine, presenting a clear vision in deep tech innovation or sustainable energy solutions is crucial. The firm values long-term commitment and strategic partnerships, aiming to support and grow foundational technologies with robust IP management and comprehensive investment strategies.

Aves Lair is a global venture capital and venture operator founded in 2020, specializing in supporting early-stage startups in the blockchain, AI, Web3, and digital asset sectors. Initially launched as a technology hub in 2018, Aves Lair has evolved into a comprehensive ecosystem that combines venture capital, acceleration, and hands-on operational support to foster growth and innovation. The firm operates with a “founder-first” approach, offering more than just financial backing. Through its in-house accelerator and incubation programs, Aves Lair captures startups at an early stage, providing critical resources such as fundraising assistance, technical development through in-house engineering teams, and strategic market access. The firm also supports its portfolio companies by securing board seats and guiding them through cross-border expansions. Aves Lair invests in projects that focus on the adoption of digital assets and disruptive technologies, with a strong network across Asia, Africa, and North America. Its portfolio includes companies like Computecoin and Digital Prime Technologies, which benefit from tailored support in everything from product development to scaling in global markets​.

Avesta Fund is a seed-stage venture capital firm founded in 2020 and based in Denver, Colorado. The firm is dedicated to investing in technology-enabled companies that focus on addressing significant global challenges, particularly those related to climate change and economic inequality. Avesta Fund places a strong emphasis on supporting diverse founding teams, aiming to drive innovation that leads to both impactful social outcomes and strong financial returns. The fund typically invests between $150,000 and $500,000 per company, focusing on scalable solutions in areas such as sustainable agriculture, energy efficiency, clean energy, and the circular economy. Avesta Fund’s investment strategy is to bridge the worlds of technology, venture capital, and impact investing, helping startups not only secure financial backing but also attract like-minded investors, colleagues, and customers. Avesta Fund is committed to fostering a new generation of companies that can generate measurable social and environmental impact while achieving commercial success. Their approach includes hands-on support to help startups navigate the challenges of early growth and scale their operations effectively.

Avestria Ventures is a California-based venture capital firm founded in 2018 by veteran life science executives Linda Greub and Corinne Nevinny. Operating from the San Francisco Bay Area and Beverly Hills, the firm invests in early-stage women's health and life science companies, with a primary focus on women-led founding teams — a market segment that has historically been underfunded relative to its commercial and clinical potential. Avestria leads rounds with typical checks of $500,000 to $5 million across pre-seed through Series A stages. The firm has made 43 investments and achieved notable portfolio exits, including Alydia Health's acquisition by Organon for up to $240 million and Uqora's acquisition by Pharmavite. Avestria closed Fund I in 2021 and has continued deploying through Fund II. With a team of 20 including 6 partners, the firm brings deep life sciences industry expertise across regulatory, clinical, and commercial pathways that matter most for health companies navigating product development to market. Avestria is one of the few dedicated venture funds at the intersection of women's health innovation and female-founded companies — a dual focus that reflects both a market conviction and an investment philosophy. The firm's large advisory network provides portfolio companies with the domain-specific guidance needed to navigate FDA processes, clinical trial design, and pharma partnership negotiations. Greub and Nevinny's combined decades of life science industry experience give Avestria a credibility advantage with founders, corporates, and co-investors that sector-agnostic funds cannot easily replicate.

Avid Ventures is a venture capital firm focused on backing early-stage startups in fintech, consumer internet, and software sectors across North America, Europe, and Israel. Founded in 2020 by Addie Lerner, formerly of General Catalyst, Avid invests primarily at Seed, Series A, and Series B stages. With a $68 million debut fund, Avid’s flexible approach allows for varied check sizes, co-leading rounds or making smaller initial investments alongside other top-tier investors. What sets Avid apart is its deep involvement in the strategic growth of its portfolio companies. The team, which includes key members like Tali Vogelstein and Irene Gendelman, works closely with founders, providing hands-on support in areas like financial modeling, business development, hiring, and fundraising strategy. Their approach is highly collaborative, with Avid acting as a dedicated extension of the startup’s team, offering outsourced strategic finance support and helping companies scale operationally. Avid’s portfolio includes a diverse range of innovative companies, such as Rapyd, a global payments platform, Nova Credit, a cross-border credit data provider, and Coast, a fintech startup. The firm is known for its founder-first mentality, emphasizing long-term partnerships and building trust through early involvement and continued support throughout the company's growth journey. This unique blend of flexibility, strategic involvement, and strong partnerships makes Avid Ventures a highly sought-after investor for transformative, high-growth startups.

Avila VC is a Miami, Florida-based venture capital firm founded in 2022 by Patricia Wexler. The firm invests at the intersection of bits and atoms — companies that combine software and physical sciences to rebuild foundational industries for abundance, sustainability, and human flourishing. Target sectors include climate technology, human health, agtech, biotech, and neural technologies, with a global investment footprint spanning the United States, United Kingdom, Australia, Israel, Brazil, and Mexico. Avila invests at pre-seed, seed, and Series A stages, with checks ranging from $250,000 to $5 million across 12 portfolio companies. Notable investments include Aionics in computational chemistry, Dig Energy in geothermal technology, and Realta Fusion in fusion energy — companies working on fundamental physical-world problems where computational approaches create scientific leverage. The portfolio reflects a conviction that the most consequential companies of the next decade will operate at the boundary between deep science and scalable software. Avila VC distinguishes itself through its focus on deep technology companies transforming foundational industries such as energy, food, and healthcare — rather than incremental software improvements. Patricia Wexler's investment thesis holds that climate, health, and abundance challenges require solutions rooted in physical science, not just digital abstraction. The firm's global geography reflects an understanding that the best founders tackling these problems are distributed worldwide, and that access to capital should not be constrained by proximity to traditional technology hubs.

Avoro Capital Advisors is a global life sciences investment firm based in New York, known for its strategic focus on biotechnology, life sciences, and specialty therapeutics. Founded as venBio Select Advisor, the firm has been instrumental in supporting emerging biotech companies that are driving innovation in the treatment of unmet medical needs. Avoro's investment strategy emphasizes identifying unique or undervalued opportunities in the market, often participating in both public and private investments across the biotech landscape. The firm’s portfolio includes a range of prominent companies such as Immunomedics (acquired by Gilead in 2020), MyoKardia (acquired by Bristol Myers Squibb), and Mirati Therapeutics, among others. Avoro is recognized for its hands-on approach, offering not just financial backing but also deep intellectual support to foster scientific breakthroughs. Avoro Ventures, a venture capital arm of the firm, extends this mission by focusing on early-stage investments in the drug discovery and healthcare tools sectors. The team is led by Managing Partner and Portfolio Manager Behzad Aghazadeh, who is highly regarded in the industry for his expertise in biopharmaceutical investments. With a comprehensive approach that includes rigorous risk management and a strong focus on innovation, Avoro Capital continues to be a key player in advancing biopharmaceutical developments.

Awesm Ventures is a San Mateo, California-based early-stage investment firm founded in 2015 by Tommaso Di Bartolo. The firm invests in startups developing Physical AI solutions — companies applying artificial intelligence and machine learning to real-world mobility and physical-world applications. Awesm operates at the intersection of AI and established mobility industries, including automotive, aviation, maritime, railroad, and oil and energy sectors, with checks ranging from $100,000 to $2 million at seed and Series A stages. The firm has built a portfolio of 12 companies and partners with mobility corporations to drive external innovation through data-driven startups. This corporate partnership model creates a distinctive dynamic: portfolio companies gain direct access to large industry incumbents as potential pilot customers, data partners, and strategic acquirers, while corporate partners gain a structured window into emerging Physical AI technologies before those technologies mature and become difficult to integrate. Awesm's differentiation lies in this bridge role between early-stage AI startups and established mobility corporations. Rather than funding companies and hoping for eventual enterprise adoption, Awesm actively cultivates relationships with mobility industry incumbents and introduces them to portfolio companies at an early stage — compressing the typical go-to-market timeline for founders selling into complex industrial buyers. For startups building AI for physical environments where data access and industry relationships are critical moats, Awesm's corporate network is a meaningful competitive advantage beyond the capital it provides.

Awesome People Ventures is an early-stage venture capital firm that focuses on investing in Web3 and other transformative technologies that are poised to reshape how we live and work. Founded by Julia Lipton, a seasoned entrepreneur and investor, the fund is dedicated to supporting founders who are not only innovative but also committed to building companies with integrity, inclusivity, and long-term impact. The firm primarily invests in startups at the pre-seed and seed stages, with a particular emphasis on those operating in the Web3 space—a sector that encompasses blockchain, decentralized finance (DeFi), and other emerging technologies that enable new forms of digital ownership, governance, and value exchange. Awesome People Ventures is driven by the belief that Web3 represents a pivotal technological and cultural shift, with the potential to fundamentally alter various industries and create more equitable systems. In addition to providing capital, Awesome People Ventures offers hands-on growth support, including strategic guidance, mentorship, and access to an exclusive talent network. This holistic approach ensures that the startups in their portfolio have the resources they need to navigate the challenges of early-stage growth and scale successfully. The firm is backed by a group of high-profile investors, including Marc Andreessen and Chris Dixon, who are known for their expertise in the crypto and technology sectors. Awesome People Ventures is committed to backing a diverse range of founders and ideas, aiming to foster innovation that leads to a more inclusive and equitable future.

AXA Venture Partners (AVP) is a global venture capital firm with more than €2 billion in assets under management. Founded in 2015, AVP focuses on investing in high-growth, technology-enabled companies across various stages, from early to late growth. Their investment sectors include enterprise software, fintech/insurtech, digital health, and consumer technology. Notable investments in AVP's portfolio include companies like Phenom People, Security Scorecard, and Virtuo. The firm leverages its connection with AXA, providing portfolio companies access to AXA’s global networks and expertise in risk management and financial services. This unique relationship allows AVP to offer significant business development support, shortening sales cycles and expanding market reach for their portfolio companies. AVP operates globally from offices in New York, London, and Paris. Their investment strategy is characterized by a multi-stage approach, focusing on product-market fit and initial traction in venture stage investments, and seeking companies with robust customer bases and significant revenue growth in growth stage investments. The leadership team includes François Robinet, the founder and managing partner, and other experienced partners such as Elizabeth de Saint-Aignan and Alex Scherbakovsky, who bring extensive expertise in technology and venture capital. For startups, AVP values exceptional founders with innovative solutions that can transform industries. Their support goes beyond financial backing, providing strategic guidance and leveraging their extensive network to help companies grow and succeed.

Axial VC is a San Francisco-based venture capital firm, founded in 2019 by Joshua Elkington. The fund is focused on early-stage investments in the biotechnology sector, with a particular emphasis on innovative therapeutics and healthcare technologies. Axial has a strong track record of backing cutting-edge startups, with notable investments including CHARM Therapeutics, which leverages AI in biotechnology, and Replay, a leader in gene therapy. Geographically, Axial’s portfolio spans across key biotech hubs in the U.S. and Europe, such as San Francisco, San Diego, and London. The fund is known for participating in sizeable funding rounds, with an average check size of around $19M, although it does not typically lead these rounds. Instead, Axial often co-invests alongside prominent firms like Khosla Ventures, General Catalyst, and OrbiMed, ensuring a collaborative approach to scaling its portfolio companies. Axial’s strategy is heavily centered on identifying transformative technologies at the intersection of biology and data science. The fund actively seeks out startups with strong scientific foundations and the potential to disrupt traditional healthcare paradigms. For entrepreneurs looking to connect with Axial, the firm values a clear demonstration of technical innovation and market potential. The team, based primarily in San Francisco, is hands-on, providing not just capital but also strategic guidance to help startups navigate the complexities of early-stage growth.